Abbott Laboratories
NYSE:ABTMedical - Devices
-$0.51 today
- Market cap
- $180.95B
- Beta
- 0.62
- P/E (TTM)
- 24.5
- EPS (TTM)
- $3.59
- Dividend yield
- 2.77%
Volume 7.02M
Average 13.17M
ABT Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Abbott LaboratoriesNYSE: ABT
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income declines year over year
Q3 FY2026 operating income of $1.48B fell 28.2% year over year, behind the -5.6% change in trailing-twelve-month operating income. Sequentially, it fell 17.2% from the prior quarter. Over 3 fiscal years it compounded at -1.3% a year.
Context
- Operating income amounted to 18.2% of revenue in FY2025, up 1.9 pp from a year earlier.
- Operating income increased in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 20 analysts of $11.69B (+45.2%) for the fiscal year ending Dec 2026, a step up from the +17.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $1.48B-17.2% QoQ
- Last fiscal yearDec 2025
- $8.05B+17.9% YoY
- LTMSep 2026
- $7.35B-5.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- 8.05B USD
- Year-over-year change
- +17.9%
- 4-year CAGR
- -3.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.05B | +17.9% |
| FY2024 | 2024-12-31 | 6.83B | +6.1% |
| FY2023 | 2023-12-31 | 6.44B | -23.0% |
| FY2022 | 2022-12-31 | 8.36B | -9.1% |
| FY2021 | 2021-12-31 | 9.2B | — |
Operating Income vs competitors
How ABT compares with its peers on the latest reported figures
- ABT's LTM Sep 2026 operating income of $7.35B is the 3rd highest of the 10 companies compared; the peer median is $5.22B.
- Its year-over-year change of -5.6% is the 8th highest of 10, against a peer median of +6.2%.
- Operating income amounts to 15.2% of revenue for ABT, versus a peer median of 20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $25.53B | +6.2% | +6.8% | 25.7% | |
| LTM Sep 2026 | $8.52B | +5.1% | -1.7% | 18.0% | |
| LTM Sep 2026 | $7.35B | -5.6% | -1.3% | 15.2% | |
| LTM Jul 2026 | $6.79B | +10.8% | +5.6% | 18.1% | |
| LTM Jun 2026 | $5.69B | +10.2% | +9.4% | 22.0% | |
| LTM Sep 2026 | $5.22B | -2.8% | -12.0% | 20.4% | |
| LTM Jun 2026 | $4.51B | +51.3% | +29.6% | 21.5% | |
| LTM Jun 2026 | $2.57B | -6.8% | +3.1% | 12.7% | |
| LTM Sep 2026 | $2.38B | -7.6% | +2.2% | 11.8% | |
| LTM Jun 2026 | $1.83B | +22.9% | -1.3% | 28.1% | |
| Peer median (excluding ABT) | $5.22B | +6.2% | +3.1% | 20.4% | |
Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 43.08B | 43.65B | 40.11B | 41.95B | 44.33B |
| Cost of Revenue | 19.86B | 21.33B | 20.07B | 20.63B | 19.72B |
| Gross Profit | 23.21B | 22.32B | 20.04B | 21.33B | 24.61B |
| Gross Margin | 53.9% | 51.1% | 50.0% | 50.8% | 55.5% |
| Research & Development | 2.74B | 2.85B | 2.72B | 2.82B | 2.96B |
| Selling, General & Admin | 11.28B | 11.11B | 10.88B | 11.65B | 12.38B |
| Operating Expenses | 14.01B | 13.96B | 13.6B | 14.47B | 16.59B |
| Depreciation & Amortization | 3.54B | 3.27B | 3.24B | 3.22B | 3.12B |
| EBITDA | 12.16B | 11.89B | 10.61B | 10.83B | 11.92B |
| EBITDA Margin | 28.2% | 27.2% | 26.4% | 25.8% | 26.9% |
| Operating Income | 9.2B | 8.36B | 6.44B | 6.83B | 8.05B |
| Operating Margin | 21.4% | 19.2% | 16.0% | 16.3% | 18.2% |
| Interest Income | 43M | 183M | 385M | 344M | 230M |
| Interest Expense | 410M | 315M | 698M | 603M | 341M |
| Other Income / Expenses | (989M) | (56M) | 229M | 188M | 418M |
| Income Before Tax | 8.21B | 8.31B | 6.66B | 7.01B | 8.47B |
| Pre-Tax Margin | 19.1% | 19.0% | 16.6% | 16.7% | 19.1% |
| Income Tax Expense | 1.14B | 1.37B | 941M | (6.39B) | 1.94B |
| Net Income | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B |
| Net Margin | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| EPS (Basic) | 3.97 | 3.94 | 3.30 | 7.67 | 3.74 |
| EPS (Diluted) | 3.94 | 3.91 | 3.27 | 7.64 | 3.72 |
| Weighted Avg Shares | 1.78B | 1.75B | 1.73B | 1.73B | 1.75B |
| Weighted Avg Shares (Diluted) | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B |
Abbott Laboratories
NYSE:ABT
Intrinsic Alpha fair value
Locked
Current Price
$104.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.